Neurofilament Light Chain Test

Your brain can be losing nerve cells for years before you feel the first symptom. By the time memory slips, balance falters, or a neurological diagnosis arrives, substantial damage may already be done. NfL (neurofilament light chain) is one of the few blood tests that can detect this process while it is still silent, giving you a window into your nervous system's health that standard bloodwork and even brain imaging can miss.

NfL is a scaffolding protein that runs along the long fibers (called axons) connecting your nerve cells. Under normal conditions, tiny amounts of it leak into your blood as part of routine cellular turnover. When nerve cells are injured, whether from inflammation, degeneration, trauma, or reduced blood supply, far more NfL spills out. The more damage, the higher the number. A simple blood draw can now pick up these elevations with enough sensitivity to distinguish normal aging from something that warrants attention.

What NfL Tells You About Your Brain

NfL is not a test for any single disease. It is a measure of how much nerve damage is happening in your body right now. Think of it as a smoke detector for your nervous system: it does not tell you where the fire is or what started it, but it tells you something is burning. Elevated levels have been documented across dozens of neurological conditions, from Alzheimer's disease and multiple sclerosis to ALS and stroke.

This lack of specificity is actually one of NfL's strengths for prevention-minded testing. A high reading means your nervous system is under stress and warrants further investigation with more targeted tests or imaging. A normal reading, especially one that stays stable over time, provides meaningful reassurance that significant nerve damage is not occurring.

Dementia and Cognitive Decline

The connection between elevated NfL and future dementia risk is among the best-studied applications of this biomarker. In the Rotterdam Study, which followed over 4,400 initially healthy adults for up to 14 years, people with higher baseline NfL were about 59% more likely to develop dementia overall and 50% more likely to develop Alzheimer's disease specifically, after adjusting for age, sex, education, cardiovascular risk, and the APOE gene. Even more striking: NfL levels began climbing roughly 9.6 years before an Alzheimer's diagnosis, rising 3.4 times faster in those who eventually developed the disease.

In families carrying genes that cause early-onset Alzheimer's, plasma NfL can distinguish mutation carriers from non-carriers as early as 22 years before symptoms begin, though the signal is weak at younger ages and becomes more reliable as symptom onset approaches. A meta-analysis of 26 studies confirmed that higher baseline NfL predicts faster cognitive decline across multiple tests, with an adjusted hazard ratio of 1.32 for progression from normal cognition or mild impairment to dementia.

When NfL is combined with other blood markers, predictive power sharpens considerably. In the Rotterdam Study, people in both the lowest quartile for amyloid beta 42 (a protein linked to Alzheimer's plaques) and the highest quartile for NfL had roughly a 15-fold higher risk of Alzheimer's compared to those in the best quartiles for both markers.

Mortality Risk

NfL is not just a neurological marker. Multiple large studies have linked elevated levels to a higher risk of dying from any cause, even in people without diagnosed brain disease. Three independent analyses of over 2,000 US adults from the NHANES survey found that each unit increase in log-transformed NfL was associated with roughly 1.9 to 2.5 times higher all-cause mortality risk over about six years of follow-up, after adjusting for demographics, lifestyle factors, kidney function, and existing conditions.

The REGARDS Study reinforced this in a biracial cohort of 917 adults (mean age 67), where each standard-deviation increase in NfL was tied to 90% higher mortality risk over 11 years. In centenarians, NfL predicted remaining lifespan as well as or better than detailed physical and cognitive assessments. These findings suggest NfL captures something about whole-body health and biological aging that goes beyond the nervous system alone.

Stroke and Cardiovascular Risk

Elevated NfL predicts stroke risk even in people with no history of cerebrovascular disease. In the Rotterdam Study, each standard-deviation increase in NfL was associated with a 27% higher risk of any stroke and a 56% higher risk of hemorrhagic stroke (bleeding in the brain) over roughly 11 years. Among adults with diabetes in the ACCORD trial, those in the highest NfL quintile were nearly 10 times more likely to have a stroke than those in the lowest quintile, and adding NfL to standard risk prediction improved accuracy significantly.

In patients with atrial fibrillation (an irregular heart rhythm that raises stroke risk), each doubling of NfL was linked to a 27% increase in stroke or blood clots traveling to other organs. NfL also predicted cardiovascular death in over 4,000 patients undergoing heart workup, with predictive accuracy exceeding 80% at one and two years.

Multiple Sclerosis and Neuroinflammation

NfL has become one of the most clinically useful blood markers in multiple sclerosis (MS). In MS, the immune system attacks the insulating coating around nerve fibers, causing inflammation and progressive nerve damage. NfL levels track the degree of this damage and respond to treatment. People with relapsing MS who started high-efficacy therapies saw their NfL levels drop by 50 to 60% within one to two years, often returning to levels seen in healthy controls.

Elevated NfL at the time of a first MS attack predicts faster disability progression, particularly in people not receiving the most effective treatments. NfL was elevated up to six years before the first clinical MS attack in individuals who later developed the disease, suggesting subclinical nerve damage begins long before a formal diagnosis.

ALS and Motor Neuron Disease

NfL shows its strongest diagnostic performance in amyotrophic lateral sclerosis (ALS), a rapidly progressive disease that destroys motor neurons. Blood NfL distinguishes ALS from healthy controls and conditions that mimic it with roughly 85% sensitivity and 82% specificity. In people with ALS, higher NfL predicts shorter survival, with those in the highest group facing roughly 4.5 times the mortality risk of those with the lowest levels. NfL rises in presymptomatic ALS gene carriers approximately one year before symptoms begin.

Reference Ranges

NfL levels rise steadily with age, roughly 2.4 to 3.3% per year in healthy people, so a single cutoff for all adults would be misleading. Kidney function also affects NfL (impaired kidneys clear it more slowly, inflating the number). The most reliable approach is to compare your result against age-adjusted reference values using the same assay your lab employs.

The following plasma reference values (97.5th percentile upper limits) come from over 1,100 cognitively healthy individuals measured on the Simoa platform. Levels above these thresholds warrant further investigation.

These values are drawn from published research using one specific assay platform (Simoa). Different platforms (Ella, Lumipulse, Siemens) can produce values that differ by 30 to 40%, so results are not interchangeable across labs. Always compare your results within the same lab over time. Men tend to have about 26% higher levels than women in healthy populations, and the sex difference narrows or disappears in rapidly progressive diseases.

Tracking Your Trend

A single NfL result is a snapshot. The real power of this test comes from watching the trend. Because NfL varies modestly between people (your normal baseline could be very different from someone else's), tracking your own number over time is far more informative than comparing a single result to a population average. The within-person variation of NfL is remarkably low: studies report a coefficient of variation of only 3 to 11%, meaning your level stays quite stable when nothing is changing in your nervous system.

An increase of 24% or more between two measurements taken at the same lab is considered statistically meaningful and worth investigating. A more conservative threshold suggests a 64% rise from your personal baseline as the upper limit of what normal fluctuation can explain. If you see a jump beyond these thresholds, it is time to explore further with imaging, more specific biomarkers, or a neurology consultation.

Get a baseline reading as early as you can. If you are making lifestyle changes aimed at brain health, retest in 6 to 12 months to see the trajectory. After that, annual testing is a reasonable cadence for most adults. If you have a family history of neurodegenerative disease or other risk factors, more frequent testing (every 6 months) gives you a tighter read on your trend.

When Results Can Be Misleading

Several factors can inflate your NfL level without reflecting true neurological disease. Kidney function is the most common culprit: NfL is partly cleared through the kidneys, so reduced kidney function (lower eGFR) leads to higher blood NfL. One study found that severely impaired kidney function was associated with 147% higher NfL levels. Always have kidney function (creatinine or eGFR) measured alongside NfL so your result can be interpreted in context.

Surgery and general anesthesia cause a significant transient spike. NfL increases by about 67% within 48 hours after surgery and continues rising, reflecting temporary neuronal stress. Postoperative delirium amplifies this further. Wait at least two to three months after any surgical procedure before drawing NfL for baseline or monitoring purposes.

Acute infections affecting the central nervous system (bacterial meningitis, viral encephalitis, COVID-19 with neurological symptoms) can cause marked NfL elevation that persists for weeks after the infection clears. Contact sports (boxing, football) cause exposure-related increases up to 4-fold, so recent participation can distort results. Diabetes and elevated HbA1c are independently associated with higher NfL. Body mass, conversely, has an inverse relationship: higher BMI tends to correlate with lower NfL at a given age.

Bortezomib, a chemotherapy drug used for multiple myeloma, causes genuine nerve damage (peripheral neuropathy) that elevates NfL in proportion to the extent of the damage. If you are on or have recently completed bortezomib treatment, elevated NfL may reflect drug-induced neuropathy rather than a separate neurological condition.